Deficiency in the Treatment Description of mTOR Inhibitor Resistance in Medulloblastoma, a Systematic Review
Open Access
- 31 December 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (1) , 464
Abstract
Medulloblastoma is a common fatal pediatric brain tumor. More treatment options are required to prolong survival and decrease disability. mTOR proteins play an essential role in the disease pathogenesis, and are an essential target for therapy. Three generations of mTOR inhibitors have been developed and are clinically used for immunosuppression and chemotherapy for multiple cancers. Only a few mTOR inhibitors have been investigated for the treatment of medulloblastoma and other pediatric tumors. The first-generation mTOR, sirolimus, temsirolimus, and everolimus, went through phase I clinical trials. The second-generation mTOR, AZD8055 and sapanisertib, suppressed medulloblastoma cell growth; however, limited studies have investigated possible resistance pathways. No clinical trials have been found to treat medulloblastoma using third-generation mTOR inhibitors. This systematic review highlights the mechanisms of resistance of mTOR inhibitors in medulloblastoma and includes IDO1, T cells, Mnk2, and eIF4E, as they prolong malignant cell survival. The findings promote the importance of combination therapy in medulloblastoma due to its highly resistant nature.Keywords
Funding Information
- King Abdullah International Medical Research Center (RC13/258/R)
This publication has 74 references indexed in Scilit:
- Novel mutations target distinct subgroups of medulloblastomaNature, 2012
- Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid TumorsJournal of Clinical Oncology, 2011
- Loss of Tsc1 In Vivo Impairs Hippocampal mGluR-LTD and Increases Excitatory Synaptic FunctionJournal of Neuroscience, 2011
- Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in MedulloblastomaScience Translational Medicine, 2010
- Discovery of NVP-LDE225, a Potent and Selective Smoothened AntagonistACS Medicinal Chemistry Letters, 2010
- Phase I Study of Everolimus in Pediatric Patients With Refractory Solid TumorsJournal of Clinical Oncology, 2007
- Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemiaBlood, 2007
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Control of Dendritic Arborization by the Phosphoinositide-3′-Kinase–Akt–Mammalian Target of Rapamycin PathwayThe Journal of Neuroscience, 2005
- TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-RapamycinJournal of Biological Chemistry, 1995